Milestone Pharmaceuticals Files 8-K on Financials
Ticker: MIST · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1408443
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Milestone Pharma dropped an 8-K detailing their financial condition and results. Check it for the latest numbers.
AI Summary
Milestone Pharmaceuticals Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Montreal, Quebec.
Why It Matters
This filing provides investors with crucial updates on Milestone Pharmaceuticals' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
- Montreal, Quebec (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Milestone Pharmaceuticals Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 12, 2024.
Where are Milestone Pharmaceuticals Inc.'s principal executive offices located?
Milestone Pharmaceuticals Inc.'s principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, CA H4M 2X6.
What is Milestone Pharmaceuticals Inc.'s telephone number?
Milestone Pharmaceuticals Inc.'s telephone number, including area code, is (514) 336-0444.
What is the Standard Industrial Classification code for Milestone Pharmaceuticals Inc.?
The Standard Industrial Classification code for Milestone Pharmaceuticals Inc. is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-11-12 09:12:40
Filing Documents
- tm2428099d1_8k.htm (8-K) — 24KB
- tm2428099d1_ex99-1.htm (EX-99.1) — 87KB
- tm2428099d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-24-116493.txt ( ) — 308KB
- mist-20241112.xsd (EX-101.SCH) — 3KB
- mist-20241112_lab.xml (EX-101.LAB) — 33KB
- mist-20241112_pre.xml (EX-101.PRE) — 22KB
- tm2428099d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On November 12, 2024, Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2024, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 12, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. By: /s/Amit Hasija Amit Hasija Chief Financial Officer Dated: November 12, 2024